TITLE

Safety of PPAR Agonists

AUTHOR(S)
HOME, PHILLIP
PUB. DATE
May 2011
SOURCE
Diabetes Care;May2011 Supplement 2, Vol. 34, pS215
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the safety of peroxisome proliferator-activated receptors (PPAR) agonists. One problem concerning the use of PPAR agonists is fluid retention. Another safety issue concerning PPAR agonist that was identified at A Diabetes Outcome Progression Trial (ADOPT) was that of bone fractures in people taking thiazolidinediones. Based on a World Health Organization/Uppsala safety surveillance report in 2003, the possibility of increased incidence in myocardial ischemia from rosiglitazone use was confirmed.
ACCESSION #
61968014

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics